Abstract
We agree with Stöllberger and Finsterer that physicians and patients alike are keenly awaiting a new oral anticoagulant that is more effective, safer and more convenient than the vitamin K antagonists. The Randomized Evaluation of Long‐Term Anticoagulation Therapy (RE‐LY) trial demonstrated that dabigatran compared with warfarin offers superior protection against stroke and systemic embolism and reduces the risk of life‐threatening and intracranial bleeding [1]. Unlike warfarin, dabigatran has a low potential for clinically important food and drug interactions and can be administered in fixed doses without routine coagulation monitoring [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
